36 reports

  • Cedar Pollen Allergy - Drug Profiles
  • RGI-1001 - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Japan
  • World
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • Cedar Pollen Allergy - Drug Profiles

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Monoclonal Antibody
  • Japan
  • World
  • Product Initiative

The drug candidate targets the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Monoclonal Antibody
  • United States
  • Company
  • AstraZeneca PLC
  • UB-221 - DRUG PROFILE

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Monoclonal Antibody
  • Pharmaceutical
  • Research And Development
  • AstraZeneca PLC

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Monoclonal Antibody
  • Therapy
  • Bristol-Myers Squibb Company
  • MEPOLIZUMAB - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Digestive System Disorder
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Chronic Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Monoclonal Antibody
  • Therapy
  • Bristol-Myers Squibb Company

The LUTE / VERSE findings were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Diego, California, US.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Chronic Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • Product Initiative

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Digestive System Disorder
  • Monoclonal Antibody
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.
  • MEPOLIZUMAB - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Medical Biotechnology
  • Monoclonal Antibody
  • Pathology
  • Targeted Therapy
  • Therapy
  • BIOSIMILAR FOR ALLERGY - DRUG PROFILE
  • SYNTHETIC PEPTIDES FOR ALLERGY - DRUG PROFILE

NA : Not Available Source: Global Markets Direct DN-## - DRUG PROFILE DRUG FOR EGG ALLERGY - DRUG PROFILE DRUG FOR EGG ALLERGY - DRUG PROFILE DRUG FOR FOOD ALLERGY - DRUG PROFILE DRUG FOR RHEUMATOID ARTHRITIS AND

  • Allergy
  • Monoclonal Antibody
  • United States
  • Company
  • Company Operations
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States

This pre-IND meeting will focus on FluCide, designated as NV-INF-##, the company' s new anti-influenza drug.

  • Influenza
  • Monoclonal Antibody
  • Vaccine
  • United States
  • BiondVax Pharmaceuticals Ltd.
  • IMMUNOLOGY DRUGS MARKET, GLOBAL, TABLE OF ALL CLINICAL STAGE PIPELINE PRODUCTS,

Food Allergy.

  • Healthcare
  • Immunology
  • Monoclonal Antibody
  • Company Financials
  • Forecast
  • MEPOLIZUMAB - DRUG PROFILE

The drug candidate inhibits GPCR and blocks the cellular responses which are involved in allergies.

  • Dermatological Condition
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • AstraZeneca PLC

Small-molecule DMARD and anti-inflammatory drugs, such as non-steroidal antiinflammatory drugs (NSAIDs) and glucocorticoids, remain first-line therapies for patients with earlystage RA (Figure ##).

  • Monoclonal Antibody
  • Market Size
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Galapagos NV

URTICARIA PIGMENTOSA IS AN ALLERGY-MEDIATED RASH COMMON IN SM PATIENTS.

  • Dermatological Condition
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • United States
  • MEPOLIZUMAB - DRUG PROFILE

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Immunotherapy
  • Monoclonal Antibody
  • Research And Development
  • Respiratory Disease
  • AstraZeneca PLC
  • Jul 09, 2015

The study is conducted as part of an agreement between GSK and the National Institute of Allergy and Infectious Diseases (NIAID).

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

THE DRUG CANDIDATE TARGETS THE ALLERGENS (DERP ##) THAT CAN TRIGGER ALLERGIES AND ASTHMA ATTACKS DIRECTLY.

  • Asthma
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Infinity Pharmaceuticals, Inc.
  • MEPOLIZUMAB - DRUG PROFILE

The company caters to allergy and asthma specialists in the US and Germany.

  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • AstraZeneca PLC
  • Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 7)

Association between drugs.

  • Arthritis
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy
  • Deals & Alliance